M&A Partners advises Corvina Foods on its sale to Activ Pharmaceuticals

M&A Partners is pleased to have advised the Directors of Corvina Foods on its successful sale to Activ Pharmaceuticals, a leading Australian manufacturer of therapeutic and cosmetic products.

This transaction comes at a time when Australia’s health and wellness sector is expanding at a rapid rate. Consumers are increasingly focused on preventive health, functional nutrition, and holistic well-being, creating strong demand for trusted, high-quality products in both food and therapeutic categories. The integration of Corvina’s expertise in protein bars, meal replacements, and low-sugar foods with Activ’s TGA and GMP-certified pharmaceutical manufacturing
capabilities will enable rapid innovation and help address evolving consumer needs.

Activ Pharmaceuticals is recognised for its commitment to quality, manufacturing a broad portfolio of liquid, cream, and semi-solid therapeutic and cosmetic products at its purpose-built facilities in NSW.

Commenting on the acquisition, Antony Lynch, Managing Director of M&A Partners, said: “The combination of Activ and Corvina – encompassing functional nutritional foods and therapeutic and cosmetic product manufacturing capabilities - represents a powerful catalyst for growth and will deliver a broader range of health & wellness product solutions to its customers. ”

M&A Partners expects to see ongoing consolidation across the health and wellness industry as companies continue to expand their product offerings and seek to enter new geographic regions across the Asia Pacific region.

Corvina was advised by Antony Lynch and Andrew Balfe at M&A Partners. Activ was advised by Jason Bignell and Fergus Calder at 333 Capital.

For further information please contact:

Antony Lynch
Mobile: 0419 919 722
Email: alynch@mapartners.com.au
Web: http://mapartners.com.au/

‍Member Socius Global Network
https://sociusglobal.net